Pulmonary arterial hypertension: challenges and achievements 2021
https://doi.org/10.38109/2225-1685-2022-1-80-89
Abstract
Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment goals achievement, COVID-19 pandemic challenges impact on routine clinical practice is demonstrated. In this review current situation in pulmonary arterial hypertension treatment goals and regular risk stratification importance are observed, based on the latest clinical trials combined specific therapy including selective prostacyclin receptor agonist selexipag is demonstrated. special attention is paid to pulmonary hypertension patients’ treatment during COVID-19 pandemic, regular risk stratification necessity is mentioned including remote patient monitoring in order to perform timely escalation in PAH-specific treatment in order to achieve low-risk status and to improve the prognosis of PAH patients.
About the Authors
E. A. Rezukhina
National Medical Research Center of Cardiology of the Ministry
of Health of the Russian Federation; Scientific
research institute of clinical cardiology named after A.L. Myasnikov
Russian Federation
Russian Federation
Elizaveta A. Rezukhina, postgraduate student of department of pulmonary hypertension and heart disease
3rd Cherepkovskaya St., 15 a, Moscow, 121552
T. V. Martynyuk
National Medical Research Center of Cardiology of the Ministry
of Health of the Russian Federation; Scientific research institute of clinical cardiology named after A.L. Myasnikov
Russian Federation
Russian Federation
Tamila V. Martynyuk, Dr. of Sci. (Med.), Head of the Department, Professor of pulmonary hypertension and heart disease
3rd Cherepkovskaya St., 15 a, Moscow, 121552
Z. S. Valieva
National Medical Research Center of Cardiology of the Ministry
of Health of the Russian Federation; Scientific Research Institute of Clinical Cardiology named after A.L. Myasnikov
Russian Federation
Russian Federation
Zarina S. Valieva, Cand. of Sci. (Med.), Researcher at the Department of Pulmonary Hypertension and Heart Disease
3rd Cherepkovskaya St., 15 a, Moscow, 121552
V. V. Gramovich
National Medical Research Center of Cardiology of the Ministry
of Health of the Russian Federation; Scientific research institute of clinical cardiology named after A.L. Myasnikov
Russian Federation
Russian Federation
Vladimir V. Gramovich, Dr. of Sci. (Med.), Senior Research Associate of department of pulmonary hypertension and heart disease
3rd Cherepkovskaya St., 15 a, Moscow, 121552
I. E. Chazova
National Medical Research Center of Cardiology of the Ministry
of Health of the Russian Federation; Scientific Research Institute named after A.L. Myasnikov;Scientific Research Institute of Clinical Cardiology
Russian Federation
Russian Federation
Irina E. Chazova, Academician of the Russian Academy of Sciences, Dr. of Sci. (Med.), Professor, Director, Head of the Department of Systemic Hypertension of the Clinical Cardiology
3rd Cherepkovskaya St., 15 a, Moscow, 121552
References
1. Galie N., Humbert M., Vachiery J.L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016. 37:67–119. https://doi.org/10.1183/13993003.01032-2015
2. Benza R.L, Gomberg-Maitland M., Elliot C.G., et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison to ESC/ERS-based risk assessment strategies. Chest 2019; 156:323–337. https://doi.org/10.1016/j.chest.2019.02.004
3. Sitbon O., Chin K.M., Channick R.N., et al. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. J Heart Lung Transplant 2020; 39:300−309. https://doi.org/10.1016/j.healun.2019.12.013
4. Sitbon, O. Pulmonary arterial hypertension: combination therapy in the modern management era. European respiratory review: an offcial journal of the European Respiratory Society vol. 19,118 (2010):348-9. doi:10.1183/09059180.00008310
5. D’Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991; 115:343–349. https://doi.org/10.7326/0003-4819-115-5-343
6. Chazova I, Martynyuk T, Valieva Z, et al. Clinical and instrumental characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry. BioMed Research International 2020: Article ID 6836973. https://doi.org/10.1155/2020/6836973
7. Чазова И.Е., Мартынюк Т.В., Валиева З.С., соавт. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал 2020; 1:78-122. [Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian Guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian Нeart Journal 2020; 1:78-122. (In Russ.)] https://doi.org/10.38109/2225-1685-2020-1-78-122
8. Мартынюк Т.В. Легочная гипертензия: Диагностика и лечение. Сер. Библиотека ФГБУ «НМИЦ кардиологии» Минздрава России. — М.: ООО «Медицинское информационное агентство», 2018: 304 с. ISBN: 978-5-6040008-0-9. [Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow: LLC «Medical Information Agency», 2018: 304 р. ISBN:978-5-6040008-0-9. (In Russ.)]
9. Hoeper M.M., Kramer T., Pan Z., et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratifcation model. Eur Respir J 2017; 50:170740. https://doi.org/10.1183/13993003.00740-2017
10. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации. https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdf
11. Benza R.L, Miller D.P., Barst R.J., et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142:448–456. https://doi.org/10.1378/chest.11-1460
12. Frost A.E., Badesch D.B., Miller D.P., et al. Evaluation of the predictive value of a clinical worsening defnition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest 2013; 144:1521–1529. https://doi.org/10.1378/chest.12-3023
13. Kylhammar D., Kjellström B., Hjalmarsson C., et al. A comprehensive risk stratifcation at early follow-updetermines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39(47):4175-4181. https://doi.org/10.1093/eurheartj/ehx257
14. Boucly A., Weatherald J., Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 170889. doi: 10.1183/13993003.00889-2017.
15. Sitbon O, Channick R, Chin MK, et al. Selexipag for the treatment of pulmonary arterial hypertension. The New England journal of medicine. 2015; vol. 373: 2522-33. https://doi.org/10.1056/NEJMoa1503184
16. Мартынюк Т.В. Оценка приверженности пациентов с легочной гипертензией лечению ингаляционным илопростом (Вентавис): итоги проспективного многоцентрового неинтервенционного исследования IVENT. Системные гипертензии. 2019; 16(2):12-27. [Martynyuk T.V. Evaluation of compliance of pulmonary hypertension patients to the treatment with inhaled iloprost (Ventavis): results of prospective, multicenter, non-interventional IVENT study. Systemic Hypertension. 2019; 16(2):12-27 (In Russ.)] https://doi.org/10.26442/2075082X.2019.2.190352
17. Mubarak K.K. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1):9-21. https://doi.org/10.1016/j.rmed.2009.07.015
18. Gaine S., Sitbon O., Channick R.N. et al. Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study. Pulmonary and Cardiovascular: Original Research. 2021; 160(1):277-286. https://doi.org/10.1016/j.chest.2021.01.066
19. Валиева З.С., Мартынюк Т.В. Клинический случай успешного применения нового селективного агониста IP-рецепторов простациклина селексипаг у пациента с идиопатической легочной гипертензией. Евразийский кардиологический журнал. 2019; 25 (4): 144-149 [Trans. into Eng. ed.: Z.S. Valieva, T.V. Martynyuk. Case Report on the Successful Use of a New Selective Prostacyclin IP Receptor Agonist, Selexipag, in a Patient with Idiopathic Pulmonary Arterial Hypertension. Eurasian heart journal. 2019; 25 (4): 150-155], https://doi.org/10.38109/2225-1685-2019-4-144-155
20. Duggan ST, Keam SJ, Burness CB. Selexipag: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2017;17(1):73-80. https://doi.org/10.1007/s40256-016-0209-9
21. Шмальц А.А., Горбачевский С.В. Возможности и ограничения для начальной комбинированной специфической терапии легочной артериальной гипертензии в Российской Федерации. Терапевтический архив. 2020; 92(12):80-85. [A.A. Shmalts, S.V. Gorbachevsky. Advantages and limitations of initial combination therapy in pulmonary arterial hypertensionpatients in Russia. Terapevticheskii arkhiv. 2020; 92(12):80-85 (In Russ.)] https://doi.org/10.26442/00403660.2020.12.000840
22. Galiè N., Barberà J.A., Frost A.E., et al. Initial Use of Ambrisentan plus Tadalafl in Pulmonary Arterial Hypertension. N Engl J Med 2015; 373(9):834-44. https://doi.org/10.1056/NEJMoa1413687
23. Chin KM, Sitbon O, Doelberg M, et al. Effcacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. American Thoracic Society. 2020; 201:A2928-A2928. https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928
24. Kim NH, Hemnes AR, Chakinala MM, et al. Patient and disease characteristics of the frst 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021 Apr; 40(4):279-288. https://doi.org/10.1016/j.healun.2021.01.006
25. Chin K., Chakinala M., Hemnes A., et al. Real-world data for selexipag in patieants with connective tissue disease-associated pulmonary arterial hypertension: a SPHERE (selexipag: the users drug registry) analysis. CHEST, 2020; 158(4):A2187-A2190. https://doi.org/10.1016/j.chest.2020.08.1875
26. Kim N., Farber H.W., Highland K., et al. PCV3 Hospitalization Rates and Association with Survival Risk at Baseline in Patients with Pulmonary Artery Hypertension (PAH) Receiving Selexipag in Real-World (RW) Clinical Practice. Value in Health. 2020;23(2):S486, ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.494
27. Lange T.J, Söderberg S., Biedermann P., et al. Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) in a Real-World Clinical Setting: Insights from the EXPOSURE Study. Oral presentation at ATS 2021. Abstract A3607. https://doi.org/10.1164/ajrccmconference.2021.203.1_MeetingAbstracts.A3607
28. Barnikel M, Kneidinger N, Klenner F, et al. Real-life data on Selexipag for the treatment of pulmonary hypertension. Pulm Circ. 2019 Jan-Mar; 9(1):2045894019832199. https://doi.org/10.1177/2045894019832199
29. Galie N., Gaine S., Channick R. et al. Long-Term Survival, Safety and Tolerability with Selexipag in Advances in Therapy 2022; 39:796–810. https:// doi.org/10.1007/s12325-021-01898-1
30. Raina A, Abraham WT, Adamson PB, et al. Limitations of right heart catheterization in the diagnosis and risk stratifcation of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. J Heart Lung Transplant. 2015 Mar; 34(3):438-47. https://doi.org/10.1016/j.healun.2015.01.983
31. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [published correction appears in Lancet. 2012 Feb; 4;379(9814):412]. Lancet. 2011;377(9766):658-666. https://doi.org/10.1016/S0140-6736(11)60101-3
32. Frantz RP, Benza RL, Kjellström B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2008; 27(7):780-788. https://doi.org/10.1016/j.healun.2008.04.009
33. Мартынюк Т.В., Алеевская А.М., Родненков О.В., соавт. Ведение пациентов с легочной артериальной гипертензией в условиях пандемии новой коронавирусной инфекции. Евразийский кардиологический журнал 2020; 2: 54-60. [Martynyuk T.V., Aleevskaya A.M., Rodnenkov O.V., et al. Management of patients with pulmonary arterial hypertension in the pandemic of a new coronavirus infection. Eurasian Нeart Journal 2020; 2:54-60]. https://doi.org/10.38109/2225-1685-2020-2-54-60.
34. Farha S. COVID-19 and pulmonary hypertension. Cleve Clin J Med 2020 May 11; ccc021. https://doi.org/10.3949/ccjm.87a.ccc021
35. Мартынюк Т.В., Чазова И.Е. Легочная артериальная гипертензия: достижения и реалии современного лечения, взгляд в будущее. Терапевтический архив. 2021; 93 (9):1009-1017. [Martynyuk T.V., Chazova I.E. Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future. Terapevticheskii arkhiv. 2021; 93(9):1009-1017 (in Russ.)] https://doi.org/10.26442/00403660.2021.09.201013
Review
For citations:
Rezukhina E.A., Martynyuk T.V., Valieva Z.S., Gramovich V.V., Chazova I.E. Pulmonary arterial hypertension: challenges and achievements 2021. Eurasian heart journal. 2022;(1):80-89. (In Russ.) https://doi.org/10.38109/2225-1685-2022-1-80-89
Views:
444
Email this article 
